Tech Company Financing Transactions

InterVenn BioSciences Funding Round

InterVenn BioSciences secured a $34 million Series B financing round on 11/18/2020. Investors included Anzu Partners, Amplify Partners and Genoa Ventures.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
Funds will be used to commercialize the company's High-Throughput-Glycoproteomic powered diagnostic for ovarian cancer; to service increasing partnership platform demand; and to accelerate development efforts for the immuno-oncology treatment response and colorectal cancer indications.

Company Information

Company Status
Private & Independent
Healthcare IT
Mailing Address
2 Tower Pl. 5th Floor
San Francisco, CA 94080
Email Address
InterVenn BioSciences aims to find solutions for the most challenging health problems. InterVenn's approach combines the analysis of glycoproteomics using mass spectrometry with data science and artificial intelligence to quickly identify potentially actionable and clinically relevant information for conditions including cancers, autoimmunity, fibrosis, and neurodegeneration.
InterVenn BioSciences LinkedIn Company Profile
Social Media
InterVenn BioSciences Company Twitter Account
Company News
InterVenn BioSciences News
InterVenn BioSciences on Facebook
InterVenn BioSciences on YouTube

Management Team

Email & Social
Chief Executive Officer
Aldo Carrascoso
  Aldo Carrascoso LinkedIn Profile  Aldo Carrascoso Twitter Account  Aldo Carrascoso News  Aldo Carrascoso on Facebook
Chief Information Officer
Randolph Barr
  Randolph Barr LinkedIn Profile  Randolph Barr Twitter Account  Randolph Barr News  Randolph Barr on Facebook
Chief Operating Officer
Erwin Estigarribia
  Erwin Estigarribia LinkedIn Profile  Erwin Estigarribia Twitter Account  Erwin Estigarribia News  Erwin Estigarribia on Facebook
Chief Scientific Officer
Klaus Lindpaintner
  Klaus Lindpaintner LinkedIn Profile  Klaus Lindpaintner Twitter Account  Klaus Lindpaintner News  Klaus Lindpaintner on Facebook
General Manager
Axel Kornerup
  Axel Kornerup LinkedIn Profile  Axel Kornerup Twitter Account  Axel Kornerup News  Axel Kornerup on Facebook
Vice President
Kaitlynn Moser
  Kaitlynn Moser LinkedIn Profile  Kaitlynn Moser Twitter Account  Kaitlynn Moser News  Kaitlynn Moser on Facebook
Vice President
Daniel Serie
  Daniel Serie LinkedIn Profile  Daniel Serie Twitter Account  Daniel Serie News  Daniel Serie on Facebook
Vice President
Ada Wong
  Ada Wong LinkedIn Profile  Ada Wong Twitter Account  Ada Wong News  Ada Wong on Facebook
VP - Bus. Development
Fadzhairi Jabar
  Fadzhairi Jabar LinkedIn Profile  Fadzhairi Jabar Twitter Account  Fadzhairi Jabar News  Fadzhairi Jabar on Facebook
VP - Bus. Development
John Leite
  John Leite LinkedIn Profile  John Leite Twitter Account  John Leite News  John Leite on Facebook
VP - General Counsel
Stephana Patton
  Stephana Patton LinkedIn Profile  Stephana Patton Twitter Account  Stephana Patton News  Stephana Patton on Facebook
VP - R & D
Xin Cong
  Xin Cong LinkedIn Profile  Xin Cong Twitter Account  Xin Cong News  Xin Cong on Facebook
VP - Regulatory Affairs
Katherine Dalao
  Katherine Dalao LinkedIn Profile  Katherine Dalao Twitter Account  Katherine Dalao News  Katherine Dalao on Facebook



Browse more venture capital transactions:

Prev: 11/18/2020: Mati venture capital transaction
Next: 11/18/2020: Hover venture capital transaction


Share this article


About Our Venture Capital Transactions Database

We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary